Statement of Changes in Beneficial Ownership (4)
January 15 2020 - 5:16PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Gerberding Julie L. |
2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc.
[
MRK
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Strat Comm, GI Pub Policy |
(Last)
(First)
(Middle)
MERCK & CO., INC., 2000 GALLOPING HILL ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/13/2020 |
(Street)
KENILWORTH, NJ 07033
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 1/13/2020 | | M | | 49536 | A | $0 | 106099.366 | D | |
Common Stock | 1/13/2020 | | M | | 33012 | A | $0 | 139111.366 | D | |
Common Stock | 1/13/2020 | | S(1) | | 102073 | D | $89.3367 (2) | 37038.366 (3) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $59.86 | 1/13/2020 | | M | | | 49536 | 5/1/2016 (4) | 4/30/2025 | Common Stock | 49536 | $0 | 0 | D | |
Stock Option (Right to Buy) | $58.22 | 1/13/2020 | | M | | | 33012 | 5/2/2015 (5) | 5/1/2024 | Common Stock | 33012 | $0 | 0 | D | |
Explanation of Responses: |
(1) | The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. |
(2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.04 to $89.61, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
(3) | Holdings include shares acquired in dividend reinvestment transactions. |
(4) | The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. |
(5) | The option became exercisable in equal installments on 5/2/2015, 5/2/2016 and 5/2/2017. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Gerberding Julie L. MERCK & CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH, NJ 07033 |
|
| EVP Strat Comm, GI Pub Policy |
|
Signatures
|
Faye C. Brown as Attorney-in-Fact for Julie L. Gerberding | | 1/15/2020 |
**Signature of Reporting Person | Date |
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024